Torrent Pharma Seeks CCI Approval for Rs 195 Billion JB Chemicals Deal

21 Jul 2025 CW Team

Ahmedabad-based Torrent Pharmaceuticals has sought clearance from the Competition Commission of India (CCI) to acquire a majority stake in J B Chemicals and Pharmaceuticals in a Rs 195 billion deal.

Upon completion, Torrent Pharmaceuticals will become India’s second most valuable pharmaceutical company.

The move follows Torrent’s June announcement to acquire a majority stake in J B Chemicals for Rs 195 billion.

“The proposed combination pertains to the acquisition of shareholding by Torrent Pharmaceuticals Ltd in J B Chemicals & Pharmaceuticals Ltd, followed by the merger of the target with the acquirer,” stated a notice filed with the CCI.

Torrent Pharmaceuticals, the flagship company of the Torrent Group, manufactures and sells pharmaceutical formulations across multiple therapeutic segments.

J B Chemicals & Pharmaceuticals is involved in manufacturing and marketing a wide range of formulations and active pharmaceutical ingredients (APIs), and also provides contract development and manufacturing organisation (CDMO) services.

The companies acknowledged horizontal overlaps in certain markets related to the manufacture and sale of pharmaceutical formulations in India.

In June, Torrent agreed to acquire 46.39 per cent stake from promoters Tau Investment Holdings Pte Ltd, an affiliate of global investment firm KKR, for around Rs 119.17 billion. Additionally, it will buy a further 2.80 per cent stake from certain JB Chemicals employees at Rs 1,600 per share, amounting to Rs 7.19 billion.

Following these purchases, Torrent will launch an open offer to acquire 26 per cent from the open market at Rs 1,639.18 per share, totalling Rs 68.43 billion, as per stock exchange norms.

This will be the second largest deal in the Indian pharmaceutical sector, after Sun Pharmaceutical Industries’ 2015 acquisition of Ranbaxy Laboratories. After the share purchase, JB Chemicals will merge into Torrent.

KKR had initially acquired a 65 per cent stake in JB Chemicals in 2020. Earlier this year, in March, KKR divested 5.8 per cent of its stake in JB Chemicals for Rs 14.6 billion via open market transactions.

Founded in 1976, JB Chemicals produces pharmaceuticals in areas including gastroenterology, dermatology and diabetes.

Torrent Pharmaceuticals, with annual revenues exceeding Rs 115 billion, is the flagship company of the Torrent Group, which generates group revenues of Rs 450 billion.

In a comparable major transaction, Sun Pharma announced in April 2014 its plan to acquire rival Ranbaxy for USD 4 billion in an all-stock deal, including USD 800 million in debt. The merger was completed after receiving regulatory approvals in March 2015.

Another significant recent deal saw Mankind Pharma acquire Bharat Serums and Vaccines last year for Rs 138 billion.

Your next big infra connection is waiting at RAHSTA 2025 – Asia’s Biggest Roads & Highways Expo, Jio World Convention Centre, Mumbai. Don’t miss out!

Ahmedabad-based Torrent Pharmaceuticals has sought clearance from the Competition Commission of India (CCI) to acquire a majority stake in J B Chemicals and Pharmaceuticals in a Rs 195 billion deal.Upon completion, Torrent Pharmaceuticals will become India’s second most valuable pharmaceutical company.The move follows Torrent’s June announcement to acquire a majority stake in J B Chemicals for Rs 195 billion.“The proposed combination pertains to the acquisition of shareholding by Torrent Pharmaceuticals Ltd in J B Chemicals & Pharmaceuticals Ltd, followed by the merger of the target with the acquirer,” stated a notice filed with the CCI.Torrent Pharmaceuticals, the flagship company of the Torrent Group, manufactures and sells pharmaceutical formulations across multiple therapeutic segments.J B Chemicals & Pharmaceuticals is involved in manufacturing and marketing a wide range of formulations and active pharmaceutical ingredients (APIs), and also provides contract development and manufacturing organisation (CDMO) services.The companies acknowledged horizontal overlaps in certain markets related to the manufacture and sale of pharmaceutical formulations in India.In June, Torrent agreed to acquire 46.39 per cent stake from promoters Tau Investment Holdings Pte Ltd, an affiliate of global investment firm KKR, for around Rs 119.17 billion. Additionally, it will buy a further 2.80 per cent stake from certain JB Chemicals employees at Rs 1,600 per share, amounting to Rs 7.19 billion.Following these purchases, Torrent will launch an open offer to acquire 26 per cent from the open market at Rs 1,639.18 per share, totalling Rs 68.43 billion, as per stock exchange norms.This will be the second largest deal in the Indian pharmaceutical sector, after Sun Pharmaceutical Industries’ 2015 acquisition of Ranbaxy Laboratories. After the share purchase, JB Chemicals will merge into Torrent.KKR had initially acquired a 65 per cent stake in JB Chemicals in 2020. Earlier this year, in March, KKR divested 5.8 per cent of its stake in JB Chemicals for Rs 14.6 billion via open market transactions.Founded in 1976, JB Chemicals produces pharmaceuticals in areas including gastroenterology, dermatology and diabetes.Torrent Pharmaceuticals, with annual revenues exceeding Rs 115 billion, is the flagship company of the Torrent Group, which generates group revenues of Rs 450 billion.In a comparable major transaction, Sun Pharma announced in April 2014 its plan to acquire rival Ranbaxy for USD 4 billion in an all-stock deal, including USD 800 million in debt. The merger was completed after receiving regulatory approvals in March 2015.Another significant recent deal saw Mankind Pharma acquire Bharat Serums and Vaccines last year for Rs 138 billion.

Real Estate

05 Sep 2025

Vitizen Hotels Signs Deal at Manyata Tech Park

Vikram Kamats Hospitality, as part of its ongoing expansion in key metropolitan markets, announced that its material subsidiary, Vitizen Hotels, has signed a long-term lease agreement for a 45-key hotel property at Manyata Tech Park, Bengaluru.Strategically located in the city’s prominent IT hub, the property is well-positioned to serve corporate travelers, business professionals, and long-stay guests. The addition aligns with the company’s asset-light growth model, leveraging long-term leases to expand its footprint in high-demand urban markets.The hotel is expected to strengthen the comp..

Infrastructure Transport

05 Sep 2025

CONCOR Signs MoU with BPIPL to Operate Container Terminal at Bhavnagar Port

Container Corporation of India (CONCOR) has signed a Memorandum of Understanding (MoU) with Bhavnagar Port Infrastructure (BPIPL) on September 4, 2025, in New Delhi to operate and maintain the upcoming container terminal at the northside of Bhavnagar Port, Gujarat.BPIPL had earlier entered into an agreement with the Gujarat Maritime Board (GMB) in September 2024 for the port’s development. Under this arrangement, 235 hectares of land has been leased to BPIPL for 30 years, with provision for expansion by an additional 250 hectares.The new terminal is expected to significantly enhance logistic..

Infrastructure Transport

05 Sep 2025

Concord Launches India’s First Indigenous Zero-Emission Rail Propulsion

Concord Control Systems (CCSL), a leader in embedded electronics and critical rail technologies, has announced the development of India’s first fully indigenous zero-emission propulsion system, marking a significant step toward the country’s railway electrification and net-zero goals for 2030.Powered by Lithium Iron Phosphate (LFP) batteries and featuring a DC chopper-based drive, the propulsion system eliminates idling losses common in diesel engines, offering higher efficiency, lower costs, and zero emissions.What sets this innovation apart is its completely indigenous design. Except for..